Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
BESTINVER Mark Giacopazzi | “Bausch + Lomb Corporation ($BLCO) is a global eye health company specializing in vision care contact lenses, surgical ophthalmic systems, and prescription ocular pharmaceuticals. Bestinver holds a strong bullish thesis centered on CEO Brent Saunders' comprehensive strategic turnaround since 2023. The manager argues that the market has fixated on temporary upfront restructuring costs and R&D ramp-up, mistaking an aggressive operational investment phase for structural margin deterioration, leaving the shares fundamentally mispriced with potential to double. From a financial and operational mechanics standpoint, the business is entering a powerful harvesting phase characterized by massive operating leverage. In Q1 2026, a 6% increase in revenue generated a near 60% surge in adjusted operating profit as newly redesigned supply chains and the integrated $2.5 billion Xiidra commercial platform supported the rapid uptake of dry-eye drug Miebo. Management targets market-outpacing revenue growth, 50% free cash flow conversion, and substantial deleveraging through 2028. Bestinver calculates intrinsic value exceeding $32 per share, representing approximately 90% upside. Key catalysts include commercial acceleration of Miebo and next-generation contact lenses, margin expansion from completed supply-chain restructuring, and debt reduction. Primary risks include the 88% controlling equity overhang from leveraged parent entity Bausch Health, potential block sale disruptions, and commercial competition from alternative dry-eye therapeutics.” | BULL | Q2 2026 Jun 30, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.